Press Release

MALVERN, Pa., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that members of its management team will present and host investor meetings at the following upcoming investor events:

• Dr. Neal Walker, President and Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY on Wednesday, February 14, 2018 at 3:30 PM EST. Management will also host investor meetings on Wednesday, February 14, 2018.
• Dr. Neal Walker, President and Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 10:00 AM EST. Management will also host investor meetings on Tuesday, March 13, 2018. 

A live webcast of the LEERINK Partners 7th Annual Global Healthcare Conference and the Cowen and Company 38th Annual Health Care Conference presentation may be accessed through the Company's web site, www.aclaristx.com, on the 'Events and Presentations' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company focuses on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne, Pennsylvania. More information can be found by visiting the Aclaris website at www.aclaristx.com.

Contact:

Aclaris Contact
Michael Tung, M.D.
Vice President / Investor Relations
484-329-2140
mtung@aclaristx.com

Media Contact
Mariann Caprino
TogoRun
917-242-1087
M.Caprino@togorun.com

Source: Aclaris Therapeutics, Inc.